Novo Nordisk CEO Lars Fruergaard Jrgensen will appear before a Senate panel to address concerns over high prices for Ozempic and Wegovy amidst calls for accountability from lawmakers.
Senator Bernie Sanders, a long-time critic of pharmaceutical pricing, questions why Novo Nordisk charges significantly more in the U.S. compared to countries like Canada and Germany.
Despite claiming that over 80% of insured Americans pay $25 or less for their diabetes drug, Novo Nordisk faces criticism for the remaining costs that burden patients.
Novo Nordisk argues that the complexity of healthcare systems in different countries influences pricing and that comparisons need to take various factors into account.
Collection
[
|
...
]